ReviewCells2023
The Implication of the Gut Microbiome in Heart Failure.
Review in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 2 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- Pharmacokinetic Alterations in Patients with Chronic Heart Failure: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Dietary strategies and nutritional supplements in the management of heart failure: a systematic review.Frontiers in nutrition · 2024Pooled it
- Trial
- Exploring the Relationship Between Sleep Disturbances, Gut Microbiota, and Cognition in Patients with Heart Failure: A Cross-Sectional Study.Medicina (Kaunas, Lithuania) · 2026Article
- Gut Microbiota and Chronic Kidney Disease: A Complex Interplay with Implications for Diagnosis and Treatment.Probiotics and antimicrobial proteins · 2026Review
- Metabolomic analysis reveals the role of gut microbiota metabolic disorders in heart failure due to congenital heart disease.Scientific reports · 2026Article
- The Heart-Gut Axis in Heart Failure: The Role of Next-Generation Pharmacological Therapies.International journal of molecular sciences · 2026Review
- The gut-heart axis in atrial fibrillation: Pathophysiology, evidence, and therapeutic potential.Heart rhythm O2 · 2026Review
- Modulating drug response through the gut microbiome: pathways to precision therapy.Archives of microbiology · 2026Review
- Gut Microbiota-Derived Metabolite and Heart Failure with Reduced Ejection Fraction (HFrEF): Elevated Trimethylamine N-Oxide (TMAO) as a Potential Biomarker.International journal of molecular sciences · 2026Article
- Shengxian decoction modulates gut microbiota and microbial metabolism in rats with chronic heart failure.Frontiers in microbiology · 2026Article
- The Gut Microbiota-NLRP3 Inflammasome Axis in Chronic Heart Failure: Mechanisms Across Heart Failure Phenotypes and Therapeutic Perspectives.Journal of inflammation research · 2026Review
- Effect ofFrontiers in medicine · 2026Article
- Gut microbiota and gut-kidney axis in kidney diseases: therapeutic potential and perspectives of natural products.Frontiers in pharmacology · 2026Review
- Review
- The effect of a sustainable diet and time-restricted eating and probiotic in heart failure with reduced ejection fraction patients: study protocol for a randomized, double-blind, and placebo-controlled trial.Nutrition journal · 2025Article
- Microbiome and Heart Failure: A Comprehensive Review of Gut Health and Microbiota-Derived Metabolites in Heart Failure Progression.Medical sciences (Basel, Switzerland) · 2025Review
- Heart Failure and Cognitive Impairment Through the Lens of the Gut Microbiome: A Narrative Review.Journal of personalized medicine · 2025Review
- Understanding the intricate interactions between microbiota and host.World journal of experimental medicine · 2025Review
- Gut Microbiota and Bacterial Extracellular Vesicles: Emerging Roles in Myocardial Remodelling and Cardiac Health.Journal of extracellular biology · 2025Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure is a worldwide health problem with important consequences for the overall wellbeing of affected individuals as well as for the healthcare system. Over recent decades, numerous pieces of evidence have demonstrated that the associated gut microbiota represent an important component of human physiology and metabolic homeostasis, and can affect one's state of health or disease directly, or through their derived metabolites. The recent advances in human microbiome studies shed light on the relationship between the gut microbiota and the cardiovascular system, revealing its contribution to the development of heart failure-associated dysbiosis. HF has been linked to gut dysbiosis, low bacterial diversity, intestinal overgrowth of potentially pathogenic bacteria and a decrease in short chain fatty acids-producing bacteria. An increased intestinal permeability allowing microbial translocation and the passage of bacterial-derived metabolites into the bloodstream is associated with HF progression. A more insightful understanding of the interactions between the human gut microbiome, HF and the associated risk factors is mandatory for optimizing therapeutic strategies based on microbiota modulation and offering individualized treatment. The purpose of this review is to summarize the available data regarding the influence of gut bacterial communities and their derived metabolites on HF, in order to obtain a better understanding of this multi-layered complex relationship.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.